CN115252899A - 一种含重组人源胶原蛋白的冻干粉及其制备方法 - Google Patents
一种含重组人源胶原蛋白的冻干粉及其制备方法 Download PDFInfo
- Publication number
- CN115252899A CN115252899A CN202211110736.5A CN202211110736A CN115252899A CN 115252899 A CN115252899 A CN 115252899A CN 202211110736 A CN202211110736 A CN 202211110736A CN 115252899 A CN115252899 A CN 115252899A
- Authority
- CN
- China
- Prior art keywords
- parts
- recombinant human
- human collagen
- freeze
- powder containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000008186 Collagen Human genes 0.000 title claims abstract description 59
- 108010035532 Collagen Proteins 0.000 title claims abstract description 59
- 229920001436 collagen Polymers 0.000 title claims abstract description 59
- 239000000843 powder Substances 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 claims abstract description 36
- 150000001413 amino acids Chemical class 0.000 claims abstract description 25
- 235000001014 amino acid Nutrition 0.000 claims abstract description 24
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 20
- 229930195725 Mannitol Natural products 0.000 claims abstract description 19
- 235000010355 mannitol Nutrition 0.000 claims abstract description 19
- 239000000594 mannitol Substances 0.000 claims abstract description 19
- 229960000271 arbutin Drugs 0.000 claims abstract description 18
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 claims abstract description 18
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 12
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims abstract description 10
- 229960003966 nicotinamide Drugs 0.000 claims abstract description 8
- 235000005152 nicotinamide Nutrition 0.000 claims abstract description 8
- 239000011570 nicotinamide Substances 0.000 claims abstract description 8
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 7
- 235000003704 aspartic acid Nutrition 0.000 claims abstract description 7
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 7
- 239000004220 glutamic acid Substances 0.000 claims abstract description 7
- 239000011268 mixed slurry Substances 0.000 claims description 33
- 238000001291 vacuum drying Methods 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 238000000859 sublimation Methods 0.000 claims description 10
- 230000008022 sublimation Effects 0.000 claims description 10
- 239000008176 lyophilized powder Substances 0.000 claims description 8
- 238000007710 freezing Methods 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 6
- 230000008014 freezing Effects 0.000 claims description 6
- 229930182555 Penicillin Natural products 0.000 claims description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 229940049954 penicillin Drugs 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 3
- 239000003223 protective agent Substances 0.000 abstract description 3
- 230000002378 acidificating effect Effects 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 5
- 210000004911 serous fluid Anatomy 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000012270 DNA recombination Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/505—Stabilizers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及重组人源胶原蛋白技术领域,具体涉及一种含重组人源胶原蛋白的冻干粉及其制备方法。冻干粉包括如下重量份数的组分:重组人源胶原蛋白20~30份,烟酰胺10~20份,熊果苷5~10份,甘露醇400~600份,氨基酸500~600份。本发明提供的冻干粉利用重组人源胶原蛋白与烟酰胺、熊果苷的协同配合作用,与重组人源胶原蛋白复配提高了重组人源胶原蛋白的稳定性,得到的冻干粉不易被降解;本发明冻干粉中甘露醇、氨基酸均起到保护剂的作用,其中甘露醇利用其分子中存在的羟基结构与其他成分作用,形成稳定的组合物,同时氨基酸优选谷氨酸和天冬氨酸的复混物,该氨基酸呈弱酸性,有利于重组人源胶原蛋白的稳定存在。
Description
技术领域
本发明涉及重组人源胶原蛋白技术领域,具体涉及一种含重组人源胶原蛋白的冻干粉及其制备方法。
背景技术
重组人源胶原蛋白,是利用DNA重组技术制备的胶原蛋白,其氨基酸序列可根据需求进行设计改进,重组的胶原蛋白的基因序列与人的基因序列高度一致,组织相容性较好,可以被人体直接吸收并参与构建胶原,帮助进行组织修复和部位填充。重组人源胶原蛋白在生产后不稳定需以冻干粉的形式进行冻干储存,现有技术中一般是将重组人源胶原蛋白与单一的赋形剂、防冻保护剂复混后低温冷冻所得,然而其技术缺陷在于,获得的冻干粉稳定性不加,导致其保质期较短。
发明内容
针对现有技术冻干粉储存效果不佳的技术问题,本发明提供一种含重组人源胶原蛋白的冻干粉及其制备方法,获得的冻干粉储存稳定,保质期时间长。
第一方面,本发明提供一种含重组人源胶原蛋白的冻干粉,包括如下重量份数的组分:重组人源胶原蛋白20~30份,烟酰胺10~20份,熊果苷5~10份,甘露醇400~600份,氨基酸500~600份。
进一步的,包括如下重量份数的组分:重组人源胶原蛋白20~25份,烟酰胺10~15份,熊果苷5~10份,甘露醇400~500份,氨基酸500~550份。
进一步的,包括如下重量份数的组分:重组人源胶原蛋白20份,烟酰胺15份,熊果苷5份,甘露醇450份,氨基酸500份。
进一步的,氨基酸为谷氨酸和天冬氨酸的复混物。
第二方面,本发明提供一种含重组人源胶原蛋白的冻干粉的制备方法,包括如下步骤:
S1、将烟酰胺、熊果苷在加热条件下溶于水获得混合浆液A;
S2、将混合浆液A降温,加入重组人源胶原蛋白,继续搅拌溶解,获得混合浆液B;
S3、将甘露醇、氨基酸投入混合浆液B搅拌,调pH,获得混合浆液C;
S4、将混合浆液C过滤除菌后分批置入西林瓶,进行低温真空干燥,获得冻干粉。
进一步的,步骤S1中,加热温度为50~60℃。
进一步的,步骤S2中,将混合浆液A降温至室温。
进一步的,步骤S3中,调pH至6~6.8。
进一步的,步骤S4中,低温真空干燥的工艺为,预冷温度为-20℃~-25℃,时间10h;冷阱温度为-32℃,冷冻时间为18~21h;升华温度为30~33℃,升华时间为10~12h;低温真空干燥过程中的真空度为-1.1~-0.1Mpa。
本发明的有益效果在于:
(1)本发明提供的冻干粉利用重组人源胶原蛋白与烟酰胺、熊果苷的协同配合作用,与重组人源胶原蛋白复配提高了重组人源胶原蛋白的稳定性,得到的冻干粉不易被降解,保质期长;
(2)本发明提供的冻干粉中甘露醇、氨基酸均起到保护剂的作用,其中甘露醇利用其分子中存在的羟基结构与其他成分作用,形成稳定的组合物,同时氨基酸优选谷氨酸和天冬氨酸的复混物,该氨基酸呈弱酸性,有利于重组人源胶原蛋白的稳定存在。
具体实施方式
为了使本技术领域的人员更好地理解本发明中的技术方案,下面将对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都应当属于本发明保护的范围。
实施例1
一种含重组人源胶原蛋白的冻干粉,包括如下重量份数的组分:重组人源胶原蛋白20份,烟酰胺15份,熊果苷5份,甘露醇450份,氨基酸500份。
所述含重组人源胶原蛋白的冻干粉的制备方法,包括如下步骤:
S1、将烟酰胺、熊果苷在加热条件下溶于水获得混合浆液A,加热温度为50℃;
S2、将混合浆液A降温至室温,加入重组人源胶原蛋白,继续搅拌溶解,获得混合浆液B;
S3、将甘露醇、氨基酸投入混合浆液B搅拌,调pH为6,获得混合浆液C,其中氨基酸为谷氨酸和天冬氨酸的复混物;
S4、将混合浆液C过滤除菌后分批置入西林瓶,进行低温真空干燥,低温真空干燥的工艺为,预冷温度为-20℃,时间10h;冷阱温度为-32℃,冷冻时间为18h;升华温度为30℃,升华时间为10h;低温真空干燥过程中的真空度为-1.1Mpa获得冻干粉。
实施例2
一种含重组人源胶原蛋白的冻干粉,包括如下重量份数的组分:重组人源胶原蛋白30份,烟酰胺10份,熊果苷10份,甘露醇400份,氨基酸600份。
所述含重组人源胶原蛋白的冻干粉的制备方法,包括如下步骤:
S1、将烟酰胺、熊果苷在加热条件下溶于水获得混合浆液A,加热温度为60℃;
S2、将混合浆液A降温至室温,加入重组人源胶原蛋白,继续搅拌溶解,获得混合浆液B;
S3、将甘露醇、氨基酸投入混合浆液B搅拌,调pH为6.8,获得混合浆液C,其中氨基酸为谷氨酸和天冬氨酸的复混物;
S4、将混合浆液C过滤除菌后分批置入西林瓶,进行低温真空干燥,低温真空干燥的工艺为,预冷温度为-25℃,时间10h;冷阱温度为-32℃,冷冻时间为21h;升华温度为33℃,升华时间为12h;低温真空干燥过程中的真空度为-0.1Mpa获得冻干粉。
实施例3
一种含重组人源胶原蛋白的冻干粉,包括如下重量份数的组分:重组人源胶原蛋白25份,烟酰胺13份,熊果苷8份,甘露醇500份,氨基酸550份。
所述含重组人源胶原蛋白的冻干粉的制备方法,包括如下步骤:
S1、将烟酰胺、熊果苷在加热条件下溶于水获得混合浆液A,加热温度为55℃;
S2、将混合浆液A降温至室温,加入重组人源胶原蛋白,继续搅拌溶解,获得混合浆液B;
S3、将甘露醇、氨基酸投入混合浆液B搅拌,调pH为6.5,获得混合浆液C,其中氨基酸为谷氨酸和天冬氨酸的复混物;
S4、将混合浆液C过滤除菌后分批置入西林瓶,进行低温真空干燥,低温真空干燥的工艺为,预冷温度为-23℃,时间10h;冷阱温度为-32℃,冷冻时间为20h;升华温度为31℃,升华时间为11h;低温真空干燥过程中的真空度为-1.0Mpa获得冻干粉。
对比例
对比例与实施例1不同的是,对比例组分中不含烟酰胺、熊果苷。
取实施例1-3及对比例制得的冻干粉样品,测定其在40d、90d、150d之后冻干粉中重组人源胶原蛋白的损失率(%),具体结果见表1所示。
表1重组人源胶原蛋白的损失率数据
由表1可以看出,实施例1-3所制得冻干粉中重组人源胶原蛋白稳定性较好,随着时间延长在150d内重组人源胶原蛋白被降解率低于1%,说明本发明制得的冻干粉保质期长,同时较对比例稳定效果明显。
尽管通过优选实施例的方式对本发明进行了详细描述,但本发明并不限于此。在不脱离本发明的精神和实质的前提下,本领域普通技术人员可以对本发明的实施例进行各种等效的修改或替换,而这些修改或替换都应在本发明的涵盖范围内/任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,可轻易想到变化或替换,都应涵盖在本发明的保护范围之内。
Claims (9)
1.一种含重组人源胶原蛋白的冻干粉,其特征在于,包括如下重量份数的组分:重组人源胶原蛋白20~30份,烟酰胺10~20份,熊果苷5~10份,甘露醇400~600份,氨基酸500~600份。
2.如权利要求1所述的含重组人源胶原蛋白的冻干粉,其特征在于,包括如下重量份数的组分:重组人源胶原蛋白20~25份,烟酰胺10~15份,熊果苷5~10份,甘露醇400~500份,氨基酸500~550份。
3.如权利要求1所述的含重组人源胶原蛋白的冻干粉,其特征在于,包括如下重量份数的组分:重组人源胶原蛋白20份,烟酰胺15份,熊果苷5份,甘露醇450份,氨基酸500份。
4.如权利要求1-3任一项所述的含重组人源胶原蛋白的冻干粉,其特征在于,氨基酸为谷氨酸和天冬氨酸的复混物。
5.一种权利要求1所述的含重组人源胶原蛋白的冻干粉的制备方法,其特征在于,包括如下步骤:
S1、将烟酰胺、熊果苷在加热条件下溶于水获得混合浆液A;
S2、将混合浆液A降温,加入重组人源胶原蛋白,继续搅拌溶解,获得混合浆液B;
S3、将甘露醇、氨基酸投入混合浆液B搅拌,调pH,获得混合浆液C;
S4、将混合浆液C过滤除菌后分批置入西林瓶,进行低温真空干燥,获得冻干粉。
6.如权利要求5所述的含重组人源胶原蛋白的冻干粉的制备方法,其特征在于,步骤S1中,加热温度为50~60℃。
7.如权利要求5所述的含重组人源胶原蛋白的冻干粉的制备方法,其特征在于,步骤S2中,将混合浆液A降温至室温。
8.如权利要求5所述的含重组人源胶原蛋白的冻干粉的制备方法,其特征在于,步骤S3中,调pH至6~6.8。
9.如权利要求5所述的含重组人源胶原蛋白的冻干粉的制备方法,其特征在于,步骤S4中,低温真空干燥的工艺为,预冷温度为-20℃~-25℃,时间10h;冷阱温度为-32℃,冷冻时间为18~21h;升华温度为30~33℃,升华时间为10~12h;低温真空干燥过程中的真空度为-1.1~-0.1Mpa。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211110736.5A CN115252899B (zh) | 2022-09-13 | 2022-09-13 | 一种含重组人源胶原蛋白的冻干粉及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211110736.5A CN115252899B (zh) | 2022-09-13 | 2022-09-13 | 一种含重组人源胶原蛋白的冻干粉及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115252899A true CN115252899A (zh) | 2022-11-01 |
CN115252899B CN115252899B (zh) | 2024-03-26 |
Family
ID=83756482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211110736.5A Active CN115252899B (zh) | 2022-09-13 | 2022-09-13 | 一种含重组人源胶原蛋白的冻干粉及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115252899B (zh) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100189669A1 (en) * | 2009-01-29 | 2010-07-29 | Tomohiro Hakozaki | Regulation of Mammalian Keratinous Tissue Using Skin and/or Hair Care Actives |
JP2016084335A (ja) * | 2014-10-22 | 2016-05-19 | 日本誠美研究院株式会社 | 凍結乾燥剤及び化粧料 |
KR20170055645A (ko) * | 2015-11-12 | 2017-05-22 | 인터올리고 주식회사 | 아텔로콜라겐 및 숙시닐화 아텔로콜라겐의 제조방법 |
WO2017102589A1 (en) * | 2015-12-14 | 2017-06-22 | Dsm Ip Assets B.V. | Composition comprising niacinamide and alpha-arbutin for skin lightening |
WO2020068665A1 (en) * | 2018-09-27 | 2020-04-02 | Fabius Biotechnology | Use of collagen binding domains to deliver products to skin |
AU2020100856A4 (en) * | 2020-01-02 | 2020-07-02 | Recom (Qingdao) Biotechnology Co. Ltd | Method for preserving freeze-dried powder capsules of phages |
US20210363226A1 (en) * | 2020-01-17 | 2021-11-25 | Shaanxi Huikang Bio-Tech Co., Ltd. | Recombinant collagen and recombinant collagen sponge material |
CN113717272A (zh) * | 2021-08-19 | 2021-11-30 | 浙江诸暨聚源生物技术有限公司 | 提高重组人源胶原蛋白稳定性的冻干保护剂 |
CN113975187A (zh) * | 2021-11-02 | 2022-01-28 | 安徽瀚海博兴生物技术有限公司 | 一种含有多肽氨基酸组合物祛皱护肤品及其制备方法 |
CN114010528A (zh) * | 2021-12-20 | 2022-02-08 | 广州栋方生物科技股份有限公司 | 一种重组人源胶原蛋白冻干粉及其制备方法 |
CN114272362A (zh) * | 2021-12-30 | 2022-04-05 | 西安德诺海思医疗科技有限公司 | 一种注射用重组蛋白冻干粉针剂及其制备方法 |
CN114983947A (zh) * | 2022-06-15 | 2022-09-02 | 浙江天妍生物科技有限公司 | 一种含有人源胶原蛋白的冻干粉及其制备方法 |
-
2022
- 2022-09-13 CN CN202211110736.5A patent/CN115252899B/zh active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100189669A1 (en) * | 2009-01-29 | 2010-07-29 | Tomohiro Hakozaki | Regulation of Mammalian Keratinous Tissue Using Skin and/or Hair Care Actives |
JP2016084335A (ja) * | 2014-10-22 | 2016-05-19 | 日本誠美研究院株式会社 | 凍結乾燥剤及び化粧料 |
KR20170055645A (ko) * | 2015-11-12 | 2017-05-22 | 인터올리고 주식회사 | 아텔로콜라겐 및 숙시닐화 아텔로콜라겐의 제조방법 |
WO2017102589A1 (en) * | 2015-12-14 | 2017-06-22 | Dsm Ip Assets B.V. | Composition comprising niacinamide and alpha-arbutin for skin lightening |
WO2020068665A1 (en) * | 2018-09-27 | 2020-04-02 | Fabius Biotechnology | Use of collagen binding domains to deliver products to skin |
AU2020100856A4 (en) * | 2020-01-02 | 2020-07-02 | Recom (Qingdao) Biotechnology Co. Ltd | Method for preserving freeze-dried powder capsules of phages |
US20210363226A1 (en) * | 2020-01-17 | 2021-11-25 | Shaanxi Huikang Bio-Tech Co., Ltd. | Recombinant collagen and recombinant collagen sponge material |
CN113717272A (zh) * | 2021-08-19 | 2021-11-30 | 浙江诸暨聚源生物技术有限公司 | 提高重组人源胶原蛋白稳定性的冻干保护剂 |
CN113975187A (zh) * | 2021-11-02 | 2022-01-28 | 安徽瀚海博兴生物技术有限公司 | 一种含有多肽氨基酸组合物祛皱护肤品及其制备方法 |
CN114010528A (zh) * | 2021-12-20 | 2022-02-08 | 广州栋方生物科技股份有限公司 | 一种重组人源胶原蛋白冻干粉及其制备方法 |
CN114272362A (zh) * | 2021-12-30 | 2022-04-05 | 西安德诺海思医疗科技有限公司 | 一种注射用重组蛋白冻干粉针剂及其制备方法 |
CN114983947A (zh) * | 2022-06-15 | 2022-09-02 | 浙江天妍生物科技有限公司 | 一种含有人源胶原蛋白的冻干粉及其制备方法 |
Non-Patent Citations (3)
Title |
---|
WATERMAN K C, ET AL: "Stabilization of pharmaceuticals to oxidative degradation", PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY * |
刘国安等: "一些抗氧化剂对蛋白质氧化降解的保护作用", 《四川大学学报(自然科学版)》, vol. 43, no. 6, pages 1418 * |
杨勇;: "美白剂复配对改善皮肤色素沉积的探索", 福建轻纺, no. 07 * |
Also Published As
Publication number | Publication date |
---|---|
CN115252899B (zh) | 2024-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101971798A (zh) | 人脐带华通氏胶组织块冻存保护液 | |
CN109512697B (zh) | 一种鸡尾酒法双色冻干粉及其制备方法 | |
CN113717272B (zh) | 提高重组人源胶原蛋白稳定性的冻干保护剂 | |
KR20130046912A (ko) | 과수 및 과채류의 꽃의 냉해 방지제 | |
CN111704677B (zh) | 一种利用冰壳法分离麦麸抗冻多糖的方法 | |
CN115252899A (zh) | 一种含重组人源胶原蛋白的冻干粉及其制备方法 | |
CN108835105A (zh) | 一种关节软骨玻璃化冷冻保护液及制备方法 | |
CN107638395A (zh) | 一种注射用盐酸多西环素冻干粉及其制备方法 | |
CN102058548B (zh) | 一种供注射用的盐酸氨溴索组合物及其制备方法 | |
CN112616831B (zh) | 一种诱导性多能干细胞保存液及其制备方法 | |
CN113476413A (zh) | 一种注射用更昔洛韦钠冻干粉的制备方法 | |
CN111568868B (zh) | 注射用托拉塞米的制备方法 | |
CN112456876B (zh) | 环保型膨润土复合材料及其制备方法 | |
CN113230216B (zh) | 一种注射用吡拉西坦冻干粉针剂及其制备方法 | |
CN108684811B (zh) | 一种降低蓝莓果冷冻损伤的方法 | |
CN103893776A (zh) | 羊传染性脓疱病毒细胞弱毒疫苗耐热冻干保护剂及其制备方法和应用 | |
CN110772487A (zh) | 一种二乙酰氨乙酸乙二胺的冻干方法 | |
CN112568219A (zh) | 用于干细胞、脐带血的低温保存液及其制备方法 | |
CN112746069B (zh) | 一种酶制剂的稳定增效方法 | |
CN110959330B (zh) | 百子莲胱抑素在提高植物细胞超低温保存后的存活率中的应用 | |
CN117243901A (zh) | 一种注射用帕瑞昔布钠冻干针剂的研制 | |
CN114586770A (zh) | 一种牙髓干细胞冻存液及冻存方法 | |
CN110292537A (zh) | 一种制备含寡肽-1的冻干粉的配方和方法 | |
CN106520678B (zh) | 一种用于培养肝源性干细胞的试剂盒 | |
CN116034986A (zh) | 一种骨髓基质干细胞冻存液及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |